skip to main content

ß3 agonist administration before reperfusion reduces infarct size and improves long term cardiac function in small and large animal models of myocardial infarction

Identifiers: SRA: SRP017600
BioProject: PRJNA184170
GEO: GSE42999
Study Type: 
Transcriptome Analysis
Submission: SRA062984
Abstract: RNA sequencing and subsequent bioinformatics analyses were performed at early reoxygenation stages in HL-1 cardiomyocytes treated or not with BRL37344 Methods: HL-1 cardiomyocytes were subjected to Hypoxia/Reoxygenation (6h/1h) with/without a ß3AR agonist (BRL37344 5µmol/L). mRNA profiles were generated by deep sequencing, in triplicate, using Illumina GAIIx.The sequence reads that passed quality filters were quantified using BWA aligned reads using RSEM. qRT–PCR validation was performed using SYBR Green assay. Results: After 6h of hypoxia followed by 1h reoxygenation, 866 genes were differentially expressed upon ß3AR stimulation by BRL37344. Among these, 177 were at least 2-fold up or downregulated. Conclusions: Our results show that Hsp70 plays a key role in the cardioprotection afforded by ß3AR agonism in cardiomyocytes during the early window of H/R. Overall design: mRNA profiles from cardiomyocyte subjected to H/R (6h/1h) with/without a ß3AR agonist were generated by deep sequencing, in triplicate, using Illumina GAIIx.

Related SRA data

6 (3.3Gbp; 2.3Gb)